Combination treatment for advanced duodenal cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs, furquinitinib and sintilimab, for people with advanced duodenal cancer that has not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have duodenal cancer that is advanced, has spread, or has come back and cannot be removed with surgery.
- You have had at least two prior treatments for your cancer.
- You are generally able to care for yourself (ECOG score 0-2).
- You have at least one tumor that can be measured or evaluated.
- You have not had other cancers in the past 5 years, except for certain types like skin cancer or cervical cancer.
- You have not had a heart attack, stroke, or blood clot in the past 6 months.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a new combination of drugs for people with advanced colorectal cancer that has not responded to standard treatments. The drugs may help your immune system fight the cancer and block its growth.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs — a chemotherapy called irinotecan liposome, a targeted therapy called fruquintinib, and an immunotherapy called sintilimab — for people with advanced stomach cancer whose disease has worsened after their first treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and FOLFOX chemotherapy) as the first treatment for advanced gastric (stomach) cancer. The goal is to see if this combination is safe and effective in shrinking tumors or slowing the cancer's growth.
Hear when a new Third-line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.